Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne Corporation (NASDAQ: TECH) has partnered with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test. This non-invasive liquid biopsy assay provides critical allograft health information, aiding in the management of kidney transplant patients by distinguishing between T-cell mediated rejection and antibody mediated rejection. Developed with the Azzi Laboratory at Harvard Medical School's Transplantation Research Center, the ExoTRU assay meets a significant need in patient care and has potential for market leadership in liquid biopsies.
Bio-Techne Corporation (NASDAQ:TECH) has published significant findings in the World Journal of Urology showcasing the ExoDx Prostate test (EPI) as a key tool for assessing low-risk prostate cancer. Conducted by Dr. Alexander Kretschmer and team, the study with 2,066 subjects indicates that an EPI score below 15.6 can prevent unnecessary radical prostatectomy in low-risk patients. The EPI test demonstrated a 100% negative predictive value for ruling out grade ≥GG3 cancer. The research suggests that up to 75% of men may avoid invasive procedures through effective active surveillance.
Bio-Techne Corporation (NASDAQ: TECH) will have its CEO, Chuck Kummeth, present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 9:20 a.m. EST. Investors can access the live webcast on the Investor Relations website. Bio-Techne specializes in developing high-quality proteins and reagents, generating approximately $931 million in net sales in fiscal 2021. With around 2,700 employees, its products are crucial for biomedical research and diagnostics, including various genomic and diagnostic tools.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) reported robust financial results for Q2 FY2022, achieving a 20% increase in net sales to $269.3 million. The organic revenue growth was 17%, with Protein Sciences leading at 19% growth, including a significant 27% rise in ProteinSimple solutions. GAAP EPS reached $1.94, contrasted with $1.15 last year, enhanced by a $28.4 million investment gain. Adjusted operating income advanced by 18% to $102.8 million, resulting in an adjusted operating margin of 38.3%.
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for Q4 2021, payable on February 25, 2022. This dividend targets all common shareholders of record as of February 11, 2022. Additionally, the Board approved a new share repurchase program allowing for the buyback of up to $400 million of common stock, commencing February 2, 2022. The number of shares repurchased will depend on market conditions and corporate requirements, with no obligation to acquire a specific amount.
Bio-Techne Corporation (NASDAQ: TECH) introduced its Stellar NIR / IR™ Detection Modules for the Jess system, enhancing fluorescence detection for low abundance proteins and facilitating multi-analyte multiplexing. The new modules allow total protein staining alongside various immunoassays, setting a high standard for western blotting sensitivity. Designed with automated, rapid results, the Stellar Modules provide low picogram sensitivity comparable to prior chemiluminescence detection and aim to minimize traditional western blotting drawbacks.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on February 1, 2022, at 8:00 a.m. CST to review its second quarter fiscal 2022 financial results. Interested parties can access the call via dial-in or online webcast. A recorded rebroadcast will be available from 11:00 a.m. CST on the same day until March 1, 2022. Bio-Techne is a leader in developing high-quality proteins, reagents, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021, employing around 2,700 staff globally.
Bio-Techne Corporation (NASDAQ: TECH) announced an updated presentation time for CEO Chuck Kummeth at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 8:15 a.m. EST. A live webcast will be available on Bio-Techne's Investor Relations website. The company specializes in developing purified proteins, reagents, and diagnostic products, achieving approximately $931 million in net sales in fiscal 2021. With around 2,700 employees, Bio-Techne supports biomedical research and clinical diagnostics through a diverse product portfolio.
Bio-Techne (NASDAQ: TECH) and Akoya Biosciences (NASDAQ: AKYA) announced a partnership to develop a groundbreaking automated spatial multiomics workflow for tissue sample analysis. The collaboration aims to enhance RNA and protein analysis at single-cell resolution, facilitating better biomarker discovery and patient stratification in diseases like cancer. The partnership leverages Akoya's PhenoCycler-Fusion System and Bio-Techne's RNAScope HiPlex v2 assay, promising to accelerate research and improve treatment outcomes for complex diseases.